ACONNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACONW
Aclarion, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.89+0.04 (+2.16%)
Close on Oct 19, 2026
- Market cap
- $4.65M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.15 (−76.49%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Aclarion, Inc. grew revenue 33.1% to $83.77K over the twelve months to Jun 30, 2026. Free cash flow was -$7.19M.
Revenue
$83.77K
+33.1% vs. a year earlier
Operating income
-$9.71M
TTM Q2 2026
Free cash flow
-$7.19M
FY2025
EPS, diluted
-$13.61
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.65M
- P/E ratio
- –
- Price to sales
- 55.55
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- -154.41%
Fundamentals
- Revenue
- $83.77K
- Net income
- -$9.20M
- EPS, diluted
- -$13.61
- Free cash flow
- -$7.19M
- Book value per share
- $6.91
- Diluted shares
- 2M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$83.77K+33.1% YoY
Gross profit
$18.22K
Operating income
-$9.71M
Net income
-$9.20M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months